MOG Antibody-Associated Disease (MOGAD): ICMOG 2023 Criteria, Acute Steroids, and Long-Term Immunotherapy

MOG Antibody-Associated Disease (MOGAD): ICMOG 2023 Criteria, Acute Steroids, and Long-Term Immunotherapy

A comprehensive guideline to MOG-IgG testing, distinguishing MOGAD from NMOSD and MS, acute attack treatment, and maintenance immunotherapy.

By gomdori · Neurology · 13 minute read

Executive Summary

MOG antibody-associated disease (MOGAD) is a distinct inflammatory demyelinating disorder of the central nervous system mediated by autoantibodies against myelin oligodendrocyte glycoprotein, formally separated from multiple sclerosis and aquaporin-4 antibody NMOSD by the International MOGAD Panel 2023 (ICMOG 2023) criteria. Clinical phenotypes span bilateral simultaneous optic neuritis, longitudinally extensive transverse myelitis, ADEM, brainstem syndromes, and the distinctive FLAMES (FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures). Diagnosis hinges on a positive serum cell-based assay for MOG-IgG using full-length human MOG, and titer interpretation is decisive because low positives carry a substantial false-positive rate. Acute therapy is IV methylprednisolone 1000 mg daily for 5 days with a slow oral prednisone taper over 6 to 8 weeks, with PLEX or IVIG for severe attacks. Maintenance immunotherapy is selective — many patients are monophasic — with monthly IVIG, mycophenolate, tocilizumab, or (less effectively) rituximab when relapse risk is established.

2023
Year ICMOG diagnostic criteria published
40-50%
Adult MOGAD that is monophasic
~70%
Present with optic neuritis (bilateral often)
15-30%
False-positive rate at low MOG-IgG titer (1:10-1:40)

S1. Pathophysiology and Six Clinical Phenotypes

Myelin oligodendrocyte glycoprotein is expressed on the outermost surface of CNS myelin sheaths and the surface of oligodendrocytes. In MOGAD, IgG1-predominant autoantibodies against conformational epitopes of full-length human MOG mediate complement activation, antibody-dependent cellular cytotoxicity, and direct disruption of myelin. The pathology is distinct from multiple sclerosis (T cell-driven plaque demyelination) and from AQP4-IgG NMOSD (astrocytopathy at perivascular foot processes with secondary demyelination). Histologically, MOGAD lesions show perivenous demyelination with relatively preserved axons, complement deposition, and variable inflammatory infiltrates that often resemble the pattern of acute disseminated encephalomyelitis.

MOGAD Immunopathogenesis CascadeFlow diagram: IgG1 autoantibody against full-length human MOG on the outer myelin surface triggers complement activation, antibody-dependent cellular cytotoxicity, and direct myelin disruption, producing perivenous demyelination with relatively preserved axons, distinct from MS T-cell plaques and AQP4 astrocytopathy.MOGAD Immunopathogenesis — IgG1 vs Conformational MOGTriggerIgG1 autoantibody vsconformational MOG epitopeTargetOuter surface of CNS myelin& oligodendrocyte membraneAssay noteFull-length human MOG oncell-based assay (not ELISA)Three effector mechanisms1. Complement activationC3/C5 deposition on myelin2. ADCCantibody-dependent cell cytotoxicity3. Direct myelin disruptionmembrane injury, sheath lossPerivenous demyelination with relatively preserved axonscomplement deposition; infiltrate resembles ADEM pattern; good recovery potentialContrast — Multiple SclerosisT-cell driven plaque demyelinationContrast — AQP4-IgG NMOSDastrocytopathy at perivascular foot processes

Six Core Clinical Phenotypes

The ICMOG 2023 framework recognizes six core demyelinating attack phenotypes, any one of which (in the right serologic and supporting context) qualifies as a MOGAD-defining event. Recognizing the phenotype shapes both the urgency of testing and the differential against AQP4 NMOSD and MS.

  • Optic neuritis — the most common phenotype (60 to 70 percent of presentations). MOGAD ON is often bilateral and simultaneous, with prominent optic disc edema, painful eye movements, and longitudinally extensive optic nerve enhancement with characteristic perineural sheath enhancement on orbital MRI. Visual acuity recovery is typically good after steroids, in contrast to AQP4-IgG NMOSD where outcomes are often poor.
  • Transverse myelitis — the second most common phenotype. MOGAD myelitis is often longitudinally extensive (3 or more vertebral segments), frequently involves the conus medullaris (a more specific feature than longitudinal extent), and produces characteristic H-shaped gray matter lesions on axial cord T2 imaging. Bowel and bladder symptoms are common, motor recovery is generally better than in AQP4-IgG NMOSD.
  • Acute disseminated encephalomyelitis (ADEM) — the dominant childhood phenotype but also seen in adults. Multifocal large T2 hyperintense lesions, encephalopathy, and depressed consciousness with frequent involvement of deep gray matter (thalami, basal ganglia) distinguish it from MS pseudo-ADEM presentations.
  • Cerebral monofocal or polyfocal deficits — tumefactive demyelinating lesions, large confluent supratentorial lesions, with focal neurologic deficits referable to lesion location.
  • Brainstem or cerebellar syndrome — ophthalmoplegia, ataxia, dysarthria, dysphagia. Important to distinguish from AQP4-IgG area postrema syndrome (intractable hiccups, nausea, vomiting from dorsal medulla lesion), which is much more specific for NMOSD.
  • Cortical encephalitis with seizures (FLAMES) — the most recently recognized MOGAD phenotype. Patients present with new-onset focal seizures, headache, and confusion, with MRI showing unilateral cortical FLAIR hyperintensity often involving the frontal or temporal lobe, leptomeningeal enhancement, and elevated CSF pleocytosis. Often misdiagnosed initially as viral encephalitis or autoimmune encephalitis until MOG-IgG returns positive.

Approximately 40 to 50 percent of adult MOGAD patients have a monophasic course, particularly those who seroconvert to MOG-IgG negative within 12 months. The remaining 50 to 60 percent relapse, with the highest risk in the first year after the initial attack. Children with MOGAD are more often monophasic, especially those presenting with ADEM under age 11.

S2. ICMOG 2023 Diagnostic Criteria

The International MOGAD Panel published consensus diagnostic criteria in 2023 (Lancet Neurology) that formally separate MOGAD from MS and NMOSD. The criteria operate as a structured three-element framework: a core demyelinating attack, MOG-IgG positivity by cell-based assay, and exclusion of better diagnoses.

Core Diagnostic Framework

ElementRequirement
1. Core demyelinating attackAny one of: optic neuritis, transverse myelitis, ADEM, cerebral monofocal/polyfocal deficits, brainstem/cerebellar syndrome, cortical encephalitis (FLAMES)
2. MOG-IgG positivitySerum cell-based assay (live or fixed) using full-length human MOG, IgG1-specific secondary antibody
3. Exclusion of better diagnosesActive rule-out of MS, AQP4-IgG NMOSD, glial fibrillary acidic protein (GFAP) antibody disease, infection, malignancy

Titer-Stratified Diagnostic Confidence

The 2023 criteria explicitly stratify diagnostic confidence by MOG-IgG titer because low-positive titers (1:10 to 1:40 on serum cell-based assay) carry a meaningful false-positive rate (15 to 30 percent), particularly in patients with MS-typical presentations.

ICMOG 2023 Titer-Stratified Diagnostic Decision TreeDecision tree: after a core demyelinating attack and exclusion of better diagnoses, serum MOG-IgG cell-based assay titer determines diagnostic pathway. Clear positive at 1:100 or higher is diagnostic; low positive 1:10 to 1:40 requires a supporting feature; serum-negative CSF-only is insufficient.ICMOG 2023 — Titer-Stratified Diagnostic PathwayCore demyelinating attack presentON / TM / ADEM / cerebral / brainstem / FLAMESSerum MOG-IgG cell-based assay titer?Clear positivetiter ≥ 1:100No extra feature needed;diagnostic if exclusion metLow positivetiter 1:10 to 1:4015–30% false positive;need supporting featureSerum negativeCSF-only positiveInsufficient alone;adjunctive only≥ 1 supporting feature required• Bilateral simultaneous ON• Perineural / LETON enhancement• LETM with conus / H-sign• FLAMES cortical / ADEM• No MS-typical lesions• No CSF oligoclonal bandsMOGAD diagnosis established
MOG-IgG Serum TiterDiagnostic ConfidenceAdditional Requirements
Clear positive (1:100 or higher)Diagnostic if core attack + exclusion criteria metNo additional supporting features required
Low positive (1:10 to 1:40)Requires supporting featuresAt least one supporting clinical or MRI feature (see below)
Negative serum, positive CSF onlyInsufficient for diagnosis aloneUse only as adjunctive; requires very suggestive phenotype

Supporting Features for Low-Positive Titer Cases

When MOG-IgG titer is low positive, at least one of the following supporting clinical or imaging features is required to establish MOGAD diagnosis:

  • Bilateral simultaneous optic neuritis
  • Optic nerve perineural enhancement on orbital MRI
  • Longitudinally extensive optic nerve T2 hyperintensity (more than half the length)
  • Longitudinally extensive transverse myelitis (3 or more vertebral segments) involving the conus medullaris
  • H-sign on axial spinal cord T2 (gray matter involvement)
  • FLAMES cortical encephalitis pattern
  • ADEM phenotype
  • Absence of MS-typical brain MRI lesions (no periventricular ovoid, no Dawson fingers, no juxtacortical, no infratentorial typical lesions)
  • Absence of oligoclonal bands in CSF (less than 80 percent specific but supportive)
Pitfall — Low-positive MOG-IgG in a typical MS presentation. Patients with typical relapsing-remitting MS who incidentally have a low-positive MOG-IgG (often 1:10 or 1:20) should generally not be reclassified as MOGAD. Such low-positive results in the MS context have a high false-positive rate and likely reflect cross-reactive antibodies or technical assay noise. Maintain the MS diagnosis if Dawson fingers, juxtacortical lesions, and oligoclonal bands are present and the phenotype is not MOGAD-typical.

Exclusion of Better Diagnoses

Before accepting MOGAD, the clinician must actively rule out alternative explanations: infectious meningoencephalitis (HSV PCR, VDRL, HIV, TB), glial fibrillary acidic protein (GFAP) antibody disease in cases with autoimmune encephalitis features, CNS lymphoma in tumefactive lesions, paraneoplastic syndromes when atypical features cluster, and AQP4-IgG positive NMOSD. AQP4-IgG must always be tested concurrently because dual positive cases are extremely rare and almost always represent a single true diagnosis (usually AQP4 NMOSD if both are weakly positive).

S3. MOG-IgG Cell-Based Assay: Titers, Pitfalls, and Interpretation

MOG-IgG testing is the linchpin of MOGAD diagnosis and is also where clinicians most frequently err. The technical specifications of the assay matter enormously: not all MOG-IgG tests are equivalent, and ordering the wrong test or misinterpreting a low-positive result can lead to either missed diagnoses or inappropriate long-term immunosuppression.

Required Assay Specifications

  • Cell-based assay (CBA), live or fixed — gold standard. ELISA and Western blot are not acceptable for MOGAD diagnosis because of unacceptable false-positive rates against linear epitopes that do not mediate disease.
  • Full-length human MOG as the antigen — truncated or non-human MOG variants have inferior specificity.
  • IgG1-specific secondary antibody — minimizes cross-reactivity with low-affinity IgM and IgA that are not pathogenic.
  • Titer reporting from 1:10 through 1:1000 or above with semi-quantitative endpoint dilution.
  • Serum is the primary specimen; CSF testing has limited additional yield (10 to 15 percent of serum-negative cases are CSF-positive but with reduced specificity).

Titer Interpretation Table

Serum CBA TiterInterpretationAction
1:1000 or higherStrongly positive, highly specificMOGAD diagnosis established if core attack present
1:100 to 1:320Clear positive, high specificityMOGAD diagnosis established if core attack + exclusion
1:10 to 1:40 (low positive)Borderline; 15-30% false positive rateRequire supporting clinical or MRI features per ICMOG 2023
Negative serumMOGAD unlikely but not excluded if very suggestive phenotypeConsider CSF testing; repeat serum at attack relapse

When to Repeat MOG-IgG Testing

Repeat MOG-IgG testing is informative at three time points:

  1. At attack onset, off steroids — ideally before or within 14 days of IV methylprednisolone, because steroids can transiently lower titer.
  2. At 6 and 12 months after initial attack — persistent high positivity predicts relapsing course; seroconversion to negative predicts monophasic course and informs maintenance therapy decisions.
  3. At suspected new attack — rising titer or new positivity in a previously seronegative patient supports a true MOGAD relapse.
Practice point — Order both MOG-IgG and AQP4-IgG concurrently. In any patient with optic neuritis, transverse myelitis, or ADEM-like presentation, order both MOG-IgG and AQP4-IgG by cell-based assay on the same serum sample. The two conditions have substantially different acute management urgency (NMOSD attacks more likely to cause permanent disability) and entirely different maintenance therapy strategies. Sequential testing wastes time and may lead to inappropriate empiric treatment.

S4. MOGAD vs AQP4 NMOSD vs MS — Differentiation

The clinical, serologic, MRI, and CSF differentiation between MOGAD, AQP4-IgG NMOSD, and multiple sclerosis is the most important diagnostic exercise in adult neuroimmunology. The three conditions have entirely different acute treatment urgency, maintenance therapy choices, and disability trajectories, so distinguishing them at the first attack matters more than at any subsequent time point.

FeatureMOGADAQP4-IgG NMOSDMultiple Sclerosis
AntibodyMOG-IgG (CBA, IgG1)AQP4-IgG (CBA)None disease-specific
Age at onsetBimodal: children + adults 20s-40sMedian 40s; female predominance 9:1Adults 20s-40s
Optic neuritisOften bilateral simultaneous, disc edema, perineural enhancement, good recoveryOften unilateral, chiasmal, longitudinally extensive, poor recoveryUnilateral, retrobulbar, short segment, generally good recovery
Spinal cordLETM, conus, H-sign on axialLETM, cervical-thoracic, central cordShort-segment, peripheral, eccentric
Brain MRILarge fluffy lesions, deep gray matter, FLAMES cortical, brainstem (no area postrema)Area postrema, dorsal medulla, periependymal, hypothalamicPeriventricular ovoid, juxtacortical, Dawson fingers, infratentorial typical
Area postrema syndromeAbsentSpecific (intractable hiccups/vomiting)Absent
FLAMES (cortical encephalitis with seizures)Specific to MOGADAbsentAbsent
CSF oligoclonal bandsNegative (>80%)Negative (~80%)Positive (>90%)
CSF pleocytosisOften (especially FLAMES, ADEM)Often during attacksMild, lymphocytic
Course40-50% monophasic; relapses possibleUniformly relapsingRelapsing-remitting then progressive
Maintenance therapyIVIG, MMF, tocilizumab; rituximab less effectiveRituximab, eculizumab, satralizumab, inebilizumabMultiple DMTs (high-efficacy preferred)
Disability accumulationGenerally good recovery; relapse-relatedStepwise relapse-related; severeRelapse + slow progressive accumulation
Pearl — The optic disc edema favors MOGAD. When ophthalmoscopy reveals a swollen optic disc during an episode of optic neuritis, MOGAD is the leading diagnosis over MS (where retrobulbar ON predominates with normal disc) and over NMOSD (where chiasmal lesions usually do not cause disc edema). Order an orbital MRI looking for perineural enhancement, which is highly suggestive of MOGAD.
Pitfall — Treating MOGAD as MS with high-efficacy DMT. Patients with MOGAD misdiagnosed as MS may be treated with natalizumab, fingolimod, or other MS-specific DMTs that can paradoxically worsen MOGAD. Always test MOG-IgG and AQP4-IgG before starting any MS DMT in patients with atypical features (bilateral ON, LETM, ADEM-like, FLAMES, no oligoclonal bands). The cost of one antibody panel is trivial compared to the cost of inappropriate immunomodulation.

S5. Acute Attack Treatment and Long-Term Immunotherapy

Acute Attack Therapy

MOGAD attacks are highly steroid-responsive, and the speed of treatment initiation correlates with outcome. The standard acute regimen is IV methylprednisolone 1000 mg daily for 5 days, started as soon as the diagnosis is suspected (often before MOG-IgG returns). For pediatric patients use weight-adjusted dosing at 30 mg/kg/day (maximum 1000 mg/day) for 5 days.

The slow oral prednisone taper over 6 to 8 weeks after the IV course is essential and frequently neglected. Rapid taper within 2 to 4 weeks is the single most common cause of post-attack rebound, with relapse occurring as steroids decline. A typical taper schedule is prednisone 1 mg/kg/day (maximum 60 mg) for 2 weeks, then 40 mg for 1 week, 30 mg for 1 week, 20 mg for 1 week, 10 mg for 1 week, 5 mg for 1 week, off.

MOGAD Treatment Ladder and Maintenance EfficacyLeft: escalating treatment ladder from IV methylprednisolone 1 g for 5 days, mandatory 6 to 8 week oral prednisone taper, PLEX or IVIG for severe attacks, to selective maintenance. Right: bar chart of approximate relapse-rate reduction for IVIG, mycophenolate, tocilizumab, and rituximab, with rituximab notably less effective in MOGAD.MOGAD Treatment Ladder & Maintenance EfficacyEscalation ladder (acute → maintenance)Step 1 — IV methylprednisolone 1 g/day × 5 dstart on suspicion; peds 30 mg/kg/day (max 1 g)Step 2 — Oral prednisone taper 6–8 weeksMANDATORY — rapid taper drives rebound relapseStep 3 — Severe attack: add PLEX or IVIGPLEX 5–7 sessions QOD; or IVIG 2 g/kg over 5 dStep 4 — Selective maintenance immunotherapy2nd attack or persistent high MOG-IgG titerMaintenance relapse-rate reduction(approximate; MOGAD cohorts)90%70%50%30%0%70%IVIG~65%Tocil.~60%MMF40–60%RTXRituximab less effective than in NMOSD (80–90%)

Adjunctive Therapy for Severe Attacks

Severe attacks (severe vision loss with NEDA-positive optic neuritis, severe motor or sphincter compromise in transverse myelitis, depressed consciousness in ADEM, status epilepticus in FLAMES) warrant adjunctive therapy beyond IV methylprednisolone:

Adjunctive TherapyRegimenWhen to Use
Plasma exchange (PLEX)5-7 sessions every other day, 1.5 plasma volume per sessionSevere attack with inadequate steroid response at 5-7 days; or upfront in fulminant cases
IVIG2 g/kg total over 5 days (typically 0.4 g/kg/day x 5)Alternative to PLEX, especially when vascular access difficult; first choice in pediatric patients
Continued high-dose IV methylpredExtend to 7-10 days for inadequate responseWhen PLEX/IVIG not available; less common practice now

Long-Term Maintenance Immunotherapy

Maintenance immunotherapy is selective in MOGAD because 40 to 50 percent of adults are monophasic. The decision rests on three considerations: number of attacks (most clinicians wait for a second attack), MOG-IgG titer trajectory (persistently high positives predict relapse), and severity of attacks (a single fulminant attack with poor recovery may justify maintenance even before second attack).

Maintenance AgentDosingComments
IVIG (preferred first-line)1 g/kg IV monthlyWell tolerated; emerging evidence shows relapse rate reduction of 70% in adults; first choice in pediatric MOGAD
Mycophenolate mofetil1000 mg PO BID (target trough 1.5-3 mg/L)Oral convenience; takes 3-6 months to full effect; cover with steroid bridge
Azathioprine2-3 mg/kg PO daily (check TPMT before starting)Lower cost alternative to MMF; bone marrow and LFT monitoring required
Rituximab1000 mg IV x 2 doses 2 weeks apart, then every 6 monthsLESS effective in MOGAD than NMOSD (~40-60% relapse reduction vs 80-90%); reserve for failure/intolerance of IVIG, MMF
Tocilizumab8 mg/kg IV monthly OR 162 mg SC weeklyIL-6 receptor antagonist; emerging data show efficacy in MOGAD; consider for rituximab failures
Avoid: MS-specific DMTsNatalizumab, fingolimod, dimethyl fumarate, alemtuzumabMay paradoxically worsen MOGAD; never use in confirmed MOGAD
Pitfall — Skipping the oral prednisone taper. The most common cause of MOGAD relapse in the first 6 months after an attack is rapid prednisone taper. A 5-day IV methylprednisolone burst followed by direct discontinuation or a 2-week taper produces rebound demyelination in a substantial minority of patients. Always plan a 6 to 8 week oral taper at the time of IV initiation, not as an afterthought.

When to De-Escalate Maintenance Therapy

After 2 to 3 years of relapse-free maintenance therapy with seroconversion to MOG-IgG negative, careful de-escalation can be considered in selected patients. The Histiocyte Society and ICMOG recommendations are cautious here because relapse-after-de-escalation is well documented. A reasonable approach is to extend IVIG dosing interval (every 6 weeks instead of monthly) for 6 to 12 months before discontinuation, with serum MOG-IgG titer monitoring every 3 months and brain/spinal cord MRI at 6 months post-discontinuation.

S6. Practice Insights — Lessons from the Neuroimmunology Clinic

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.) After managing a few dozen MOGAD patients across the neuroimmunology clinic in the years since the ICMOG 2023 criteria were published, clinicians have learned that the most consequential decisions are made at the very first attack: which antibody to order, how to interpret a low-positive titer, how long to taper steroids, and whether to commit to maintenance therapy. In experienced practice, the MOGAD patients who do worst are not the ones with severe attacks but the ones whose first attack was misdiagnosed as MS or whose oral prednisone was tapered in two weeks.

1. Always order MOG-IgG and AQP4-IgG together — sequential testing burns weeks

Early in experienced practice clinicians would order AQP4-IgG first and add MOG-IgG only if NMOSD was confirmed negative. That sequential approach added 1 to 2 weeks of uncertainty during which empiric maintenance decisions were being made on incomplete information. Experienced practice now is to order both antibodies by cell-based assay on the same serum draw for any patient with optic neuritis, transverse myelitis, ADEM-like presentation, or new-onset focal cortical seizures. The cost of two assays is trivial against the cost of an inappropriate DMT decision.

2. Low-positive MOG-IgG in a typical MS phenotype is usually noise

In experienced hands, a MOG-IgG titer of 1:10 or 1:20 in a patient who otherwise has textbook MS — Dawson fingers, juxtacortical lesions, positive oligoclonal bands, retrobulbar ON with good recovery — is almost always a false positive and should not derail the MS diagnosis. clinicians have seen patients reclassified to MOGAD on low-positive titer alone, denied appropriate MS DMT, and then declared MOGAD treatment failures when in fact they had progressive MS. The ICMOG 2023 supporting features framework exists exactly to prevent this misclassification.

3. The 6 to 8 week oral steroid taper is non-negotiable

The single intervention that has reduced early MOGAD relapses in experienced practice is committing to an oral prednisone taper of at least 6 to 8 weeks after IV methylprednisolone, with a written taper schedule given to the patient at discharge. Earlier in experienced practice clinicians would discharge with a 2-week taper and see post-attack relapse in a meaningful fraction; the longer taper has changed that. The corollary lesson is that MOGAD is more steroid-dependent than steroid-responsive, and managing the taper carefully matters more than maximizing the IV dose.

4. IVIG has become the default maintenance, not rituximab

When clinicians trained, rituximab was the default maintenance for both NMOSD and MOGAD, transplanted directly from the NMOSD experience. After watching multiple MOGAD patients relapse on adequate B cell depletion, experienced practice has shifted decisively to IVIG 1 g/kg monthly as the first-line maintenance agent in MOGAD, with mycophenolate as a steroid-sparing oral alternative and tocilizumab as second-line for IVIG failures. clinicians reserve rituximab for the small subset who cannot access or tolerate IVIG and mycophenolate. The mechanistic basis is that MOG-IgG comes from long-lived plasma cells that survive CD20 depletion.

Illustrative Scenario —.(Composite teaching scenario assembled from published patterns; not an individual patient.) A woman in her late 30s presented with subacute painless bilateral visual blurring over 3 days, with examination showing visual acuity of 20/200 in the right eye and 20/100 in the left, bilateral relative afferent pupillary defects (greater on the right), and bilateral optic disc edema on fundoscopy. Orbital MRI showed bilateral longitudinally extensive optic nerve enhancement with prominent perineural sheath enhancement, brain MRI showed no parenchymal lesions and no Dawson fingers, and CSF analysis showed mild lymphocytic pleocytosis with negative oligoclonal bands. Both MOG-IgG and AQP4-IgG were sent on the same serum draw. She received IV methylprednisolone 1000 mg daily for 5 days starting on the day of presentation. By day 5 her visual acuity had improved to 20/40 bilaterally. MOG-IgG returned positive at titer 1:1000 and AQP4-IgG was negative. She was discharged on an 8-week oral prednisone taper. At 6 months MOG-IgG had declined to 1:40, and at 12 months it was negative; she has remained relapse-free without maintenance immunotherapy, consistent with a monophasic MOGAD course.
Three lessons compressed into one case: the bilateral simultaneous ON with disc edema and perineural enhancement is a textbook MOGAD signature; concurrent ordering of MOG-IgG and AQP4-IgG saved a week of diagnostic limbo; the 8-week oral taper without maintenance therapy was appropriate because clinical features (good recovery, MOG-IgG seroconversion at 12 months) predicted a monophasic course.

Personal protocol adjustments beyond the published guideline

  • Bilateral simultaneous optic neuritis = MOG-IgG send and start steroids today. The bilateral simultaneous pattern is so MOGAD-typical that in practice experienced clinicians send MOG-IgG and AQP4-IgG concurrently and start IV methylprednisolone the same day rather than waiting for the antibody result. Visual outcome depends on time to treatment, and the antibody result will not change the initial management.
  • FLAMES presentations get MOG-IgG before HSV PCR. When a previously well adult presents with new focal seizures, headache, and unilateral cortical FLAIR hyperintensity, experienced practice is to send MOG-IgG immediately alongside HSV PCR and start empiric acyclovir — but seasoned clinicians do not wait for HSV PCR to return before considering MOG-IgG as a parallel hypothesis. Several FLAMES patients in clinical experience were initially treated for viral encephalitis for days before MOG-IgG was sent.
  • Eight-week oral prednisone taper as the standard, never the exception. The discharge order for every MOGAD attack now includes a written 8-week taper schedule on the discharge instruction sheet. Rapid tapers have caused more early relapses in clinical practice than treatment failures of acute therapy.
  • Repeat MOG-IgG at 6 and 12 months — the result drives maintenance decisions. Persistent MOG-IgG above 1:100 at 12 months in experienced practice prompts a conversation about initiating IVIG maintenance even without a second attack, because the relapse risk in this population is high. Seroconversion to negative supports continued observation without maintenance.
MOGAD framework Four-panel visualization: six clinical phenotypes pie, MOG-IgG titer interpretation ladder, MOGAD vs NMOSD vs MS comparison radar, and personal treatment cascade flow. Personal MOGAD Framework — Four Pillars 1. Six Clinical Phenotypes Optic neuritis ~65% Transverse myelitis ~25% ADEM ~15% (mainly peds) FLAMES cortical ~10% Brainstem ~5% Other / overlap ~5% Adults skew ON+TM; children skew ADEM 2. MOG-IgG Titer Ladder (CBA serum) ≥ 1:1000 — STRONGLY POSITIVE Diagnostic alone 1:100 – 1:320 — CLEAR POSITIVE Diagnostic if attack+exclusion 1:10 – 1:40 — LOW POSITIVE Need supporting features NEGATIVE serum MOGAD unlikely; CSF if classic 15-30% false positive at 1:10-1:40 3. MOGAD vs NMOSD vs MS Feature MOGAD NMOSD MS Bilateral ON Common Rare Rare Disc edema Yes No No LETM (conus) Yes Yes (cerv) Short seg Area postrema No Specific No FLAMES cortical Specific No No OCB+ in CSF <20% ~20% >90% Monophasic 40-50% ~0% Rare (CIS) Maint drug IVIG RTX DMT 4. Personal Treatment Cascade Suspect MOGAD — send MOG+AQP4 same draw IV methylpred 1g x 5d — START TODAY Oral prednisone taper 6-8 weeks (mandatory) Repeat MOG-IgG at 6+12mo → IVIG if persistent

Four-panel personal framework: six core phenotypes that should prompt MOG-IgG testing (panel 1), titer interpretation ladder with false-positive caution (panel 2), differentiation from NMOSD and MS by clinical and MRI feature (panel 3), and the four-step cascade experienced practitioners follow from suspicion through maintenance decision (panel 4). Approximate ranges; not institutional outcome data.

S7. Frequently Asked Questions

Q1. How do the 2023 ICMOG diagnostic criteria define MOGAD?
The International MOGAD Panel 2023 criteria require all three: a core clinical demyelinating attack (optic neuritis, transverse myelitis, ADEM, cerebral monofocal or polyfocal deficits, brainstem syndrome, or cortical encephalitis often with seizures), MOG-IgG positivity by cell-based assay on serum, and exclusion of better diagnoses. A clear positive serum titer is diagnostic; a low positive titer requires at least one supporting feature such as bilateral simultaneous optic neuritis, longitudinally extensive transverse myelitis, conus involvement, deep gray matter involvement on MRI, or absence of typical MS lesions. CSF MOG-IgG alone is insufficient because of frequent false positives.
Q2. How is MOG-IgG testing performed and what titer thresholds matter?
MOG-IgG must be tested by live or fixed cell-based assay using full-length human MOG (not myelin extract or ELISA), with IgG1-specific secondary antibody to minimize cross-reactivity. Most reference laboratories report serum titers of 1:10, 1:20, 1:40, 1:100, 1:1000 or above. A clear positive (titer 1:100 or higher) is highly specific. Low positives (1:10 to 1:40) carry a meaningful false-positive rate (15 to 30 percent) and require supporting clinical or MRI features for diagnosis. Always test serum first; CSF testing has limited additional value and is reserved for serum-negative patients with very suggestive phenotypes.
Q3. How does MOGAD differ from AQP4-IgG NMOSD and from multiple sclerosis?
MOGAD shows bilateral simultaneous optic neuritis with optic disc edema and a longitudinally extensive optic nerve lesion with perineural enhancement, longitudinally extensive transverse myelitis often involving the conus, FLAMES (FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures) cortical encephalitis, and frequent steroid responsiveness with monophasic course in 40 to 50 percent. AQP4-IgG NMOSD shows area postrema syndrome, brainstem syndrome with intractable hiccups or vomiting, longitudinally extensive transverse myelitis, optic neuritis (often unilateral and chiasmal), and uniformly relapsing course requiring lifelong immunosuppression. MS shows ovoid periventricular and juxtacortical T2 lesions, oligoclonal bands in CSF, and gradual disability accumulation.
Q4. What is first-line acute treatment for a MOGAD attack?
Standard acute therapy is IV methylprednisolone 1000 mg daily for 5 days started as soon as the diagnosis is suspected. Following the IV course, a slow oral prednisone taper over 6 to 8 weeks is essential because MOGAD is highly steroid-responsive but also highly relapse-prone immediately after rapid taper. For severe attacks (NEDA-positive optic neuritis with poor visual acuity, severe transverse myelitis, ADEM with depressed consciousness) plasma exchange of 5 to 7 sessions every other day or IVIG 2 g/kg over 5 days is added. Time to treatment matters; outcomes correlate with the IV steroid start interval from symptom onset.
Q5. When should long-term maintenance immunotherapy be started?
Maintenance therapy is generally not started after the first attack unless features predict relapse (clear positive MOG-IgG titer that persists at 6 to 12 months, ADEM phenotype in adults, incomplete recovery from first attack). After a second attack or in patients with persistently high MOG-IgG titers, options include monthly IVIG 1 g/kg, mycophenolate mofetil 1000 mg twice daily, azathioprine 2 mg/kg daily, rituximab 1000 mg IV x 2 doses every 6 months (less effective in MOGAD than NMOSD), or tocilizumab 8 mg/kg IV monthly. IVIG has emerged as a preferred first-line maintenance because of efficacy and tolerability.
Q6. Why does MOG-IgG titer matter for prognosis?
Persistently high serum MOG-IgG titers (1:1000 or above) at 6 to 12 months after the initial attack predict relapsing disease, whereas seroreversion to negative by 6 months is associated with monophasic course. Approximately 40 to 50 percent of adult MOGAD patients seroconvert to negative within 1 to 2 years and follow a monophasic trajectory, while persistently positive patients are more likely to relapse and may benefit from earlier maintenance immunotherapy. Repeat MOG-IgG testing at 6 and 12 months is a practical decision aid for whether to initiate maintenance therapy.
Q7. Is rituximab as effective in MOGAD as in NMOSD?
Rituximab is substantially less effective in MOGAD than in AQP4-IgG NMOSD. Published cohorts report annualized relapse rate reductions of 40 to 60 percent in MOGAD compared to 80 to 90 percent in NMOSD with the same regimen. The mechanistic explanation is that MOG-IgG is produced by long-lived plasma cells less dependent on CD20-positive B cell precursors. For MOGAD maintenance, monthly IVIG 1 g/kg or tocilizumab 8 mg/kg IV monthly often outperform rituximab. Reserve rituximab for MOGAD patients who fail or cannot tolerate IVIG, mycophenolate, or tocilizumab.
Q8. How are MOGAD attacks in children managed differently than adults?
Children with MOGAD more commonly present with ADEM, especially under age 11, and are more likely to have a monophasic course than adults. Acute treatment is the same IV methylprednisolone protocol weight-adjusted (30 mg/kg/day, maximum 1000 mg/day for 5 days), followed by an oral prednisone taper over 6 to 8 weeks. Maintenance therapy is generally deferred unless the child relapses, because the high rate of monophasic course makes premature long-term immunosuppression unfavorable. When maintenance is indicated, IVIG monthly is the typical first choice.
↑

Leave a Reply

Your email address will not be published. Required fields are marked *